BeStock  
Stocks › Biotechnology › ABUS

Arbutus Biopharma ABUS

US equityMarket cap rank #3471Biotechnology
$4.02 −$0.05 (-1.23%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $3.98 -1.00%
Open$4.01
Prev close$4.07
Day range$3.97 – $4.09
Volume2.99M
Market cap$616.24M
P/E (TTM)3.6
Dividend yield–

Ownership & positioning

Who holds it, who is betting against it, and where the big money is moving

Institutional ownership114.7%+23.53 pts vs. prior quarter
Institutions holding225+22 vs. prior quarter
Insider trades (recent)29 buys / 21 sellsNet buying
Short interest10.04% of floatDays to cover 9.1 · as of 30 Oct 2026
Short-sale volume share23.2%5-day average of daily volume

Short-sale volume as % of daily volume

14%20%26%31%Oct '26Oct '26Nov '26

Large-order net flow, last 20 sessions

Net of large-order buying minus selling, in USD. Over this window: −$80.3K (10 inflow days, 10 outflow days).

Net flow by order size, last 20 sessions

+$649.3KSuper−$729.6KBig−$498.4KMid−$2.1MSmall

Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.

The five largest holders on file together own 63.3% of shares outstanding.

Largest holders

  • Roivant Sciences Ltd.19.49%
  • Morgan Stanley Investment Management Inc.12.19%
  • Morgan Stanley11.99%
  • Whitefort Capital Management, LP10.30%
  • BlackRock9.35%
  • Two Seas Capital LP5.31%
  • Rubric Capital Management LP4.91%
  • State Street Global Advisors3.58%

By investor type

  • Mutual Fund46.78%
  • Public Company37.02%
  • Hedge Fund26.32%
  • Private Company2.68%
  • Family Office/Trust1.01%
  • Individual/Insider1.00%
  • Government Pension Fund0.60%
  • Insurance Company0.21%

Reported short interest has risen from 9.33% to 10.04% of float over the last 6 biweekly reports (14 Aug 2026 to 30 Oct 2026).

Recent institutional activity

HolderTypePeriodShare changeNew stake
Morgan Stanley Investment Management Inc. Mutual Fund 2026/Q3 +1,560,566 12.2%
Barclays PLC Public Company 2026/Q3 +1,191,316 0.8%
Los Angeles Capital Management LLC Mutual Fund 2026/Q3 +780,849 0.9%
First Trust Advisors L.P. Mutual Fund 2026/Q3 +696,258 0.5%
Morgan Stanley Public Company 2026/Q3 +677,741 12.0%
Assenagon Asset Management S.A. Mutual Fund 2026/Q3 +620,717 0.4%
Jane Street Group, LLC Private Company 2026/Q3 +571,080 0.4%
BlackRock Mutual Fund 2026/Q3 +565,661 9.3%
Boussard & Gavaudan Gestion S.A.S. Mutual Fund 2026/Q3 +550,000 0.4%
Carrera Capital Advisors, LLC Mutual Fund 2026/Q3 +324,977 0.4%
Nuveen Asset Management LLC Insurance Company 2026/Q3 +278,951 0.2%
Nomura Holdings, Inc. Public Company 2026/Q3 +1,637,081 1.1%
Goldman Sachs Asset Management, L.P. Mutual Fund 2026/Q3 +1,602,576 0.9%
State Street Global Advisors Mutual Fund 2026/Q3 +1,526,669 4.0%
Bank of America Corporation Public Company 2026/Q3 +962,569 1.7%

Institutional buy/sell activity by reporting period, largest moves first.

Insider transactions

DateInsiderTitleTransactionSharesPriceHeld after
30 Sep 2026 Robert Beardsley Independent Director Sale to Issuer -17,948 $5.00 14,328
30 Sep 2026 Roger Sawhney Independent Director Sale to Issuer -17,142 $5.00 13,683
30 Sep 2026 Roivant Sciences Ltd. Sale to Issuer -8,967,383 $5.00 29,880,079
30 Sep 2026 Lindsay Androski Chairperson & CEO Sale to Issuer -24,655 $5.00 19,682
30 Sep 2026 Tuan Nguyen Chief Financial Officer Sale to Issuer -48,081 $5.00 38,382
17 Sep 2026 Robert Beardsley Independent Director Derivative Exercise and Sale -99,057 $5.07 32,276
17 Sep 2026 Robert Beardsley Independent Director Derivative Exercise and Retained +32,276 $3.20 32,276
17 Sep 2026 Roger Sawhney Independent Director Derivative Exercise and Sale -100,508 $5.07 30,825
17 Sep 2026 Roger Sawhney Independent Director Derivative Exercise and Retained +30,825 $3.34 30,825
17 Sep 2026 Lindsay Androski Chairperson & CEO Derivative Exercise and Sale -82,527 $5.07 72,337
17 Sep 2026 Lindsay Androski Chairperson & CEO Derivative Exercise and Retained +44,337 $3.20 72,337
17 Sep 2026 Tuan Nguyen Chief Financial Officer Derivative Exercise and Sale -206,637 $5.07 159,963
17 Sep 2026 Tuan Nguyen Chief Financial Officer Derivative Exercise and Retained +86,463 $3.49 159,963
7 Jun 2026 Robert Beardsley Independent Director Other Derivative Acquisition +78,800 $4.24 78,800
7 Jun 2026 Roger Sawhney Independent Director Other Derivative Acquisition +78,800 $4.24 78,800
1 Feb 2026 Lindsay Androski Chairperson & CEO Other Acquisition +28,000 – 28,000
1 Feb 2026 Lindsay Androski Chairperson & CEO Other Derivative Acquisition +71,700 $4.39 71,700
1 Feb 2026 Tuan Nguyen Chief Financial Officer Other Acquisition +73,500 – 73,500
1 Feb 2026 Tuan Nguyen Chief Financial Officer Other Derivative Acquisition +188,400 $4.39 188,400
3 Aug 2025 Roger Sawhney Independent Director Other Derivative Acquisition +157,600 $3.34 157,600

From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.

Short interest, by report

Report dateShares short% of floatDays to cover
30 Oct 2026 19,888,395 10.0% 9.1
15 Oct 2026 24,566,591 12.4% 4.3
30 Sep 2026 34,053,358 17.2% 3.5
15 Sep 2026 18,484,910 9.3% 5.0
31 Aug 2026 18,916,119 9.5% 3.1
14 Aug 2026 18,456,085 9.3% 15.1

Discussion

No comments yet — be the first to weigh in on ABUS.

Sign in to join the discussion.

Scroll to Top